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Investigation  of  the  Relative  Infectivity and Pathogenicity  of  Different 
Hepatitis C Virus  Genotypes  in  Hemophiliacs 
By Lisa M. Jarvis,  Christopher A. Ludlam, Jennifer A. Ellender, Laszlo Nemes, Stephen P. Field, Ernest Song, 
Ampaiwan Chuansumrit, F. Eric Preston, and Peter Simmonds 
To  assess the relative infectivity and pathogenicity of vari- 
ants of hepatitis C  virus  (HCV)  genotypes, the distribution 
of genotypes in hemophilic patients who had  been treated 
with nonvirally inactivated factor  concentrates or  cryopre- 
cipitates prepared from local  blood  donors was compared 
with those  found in the respective blood donor  populations. 
Genotype frequencies differed markedly in the four coun- 
tries investigated (Scotland,  Hungary, South Africa,  and 
HE MAJORITY of hemophiliacs treated with pooled 
blood products before the mid 1980s have been in- 
fected with hepatitis C virus (HCV)'" and it is generally 
accepted that HCV is responsible for most of the chronic 
liver disease observed in these patients. HCV  can be classi- 
fied into several distinct genotypes whose distributions show 
regional and ethnic and considerable attention 
has recently focused on the possibility that biologic differ- 
ences exist between different HCV types. In particular, cer- 
tain  HCV variants might differ in their relative pathogenicity, 
ie, in their infectivity, persistence, or replication. This possi- 
bility can be tested by comparing the relative frequencies of 
different genotypes in hemophiliacs that have been multiply 
exposed to nonvirally inactivated factor concentrates with 
those of the blood donor population from whose donations 
blood products were manufactured. In hemophiliacs, multi- 
ple exposure to  HCV from long-term use of nonvirally inacti- 
vated concentrates has been shown to lead to multiple infec- 
tions'  and possibly an increased likelihood of acquiring more 
pathogenic variants when compared to single-exposed indi- 
viduals. 
In this study, comparisons were made between hemophili- 
acs and blood donors from countries that differed consider- 
ably in geographical HCV genotype distribution. Differences 
in pathogenicity, if they exist between HCV variants, should 
be manifested by an increased or reduced frequency of detec- 
tion of certain genotypes in the hemophiliacs compared with 
blood donors from whom  blood products were manufactured 
in each of the countries. 
A further comparison was made  between  HCV genotype 
distributions in hemophiliacs who have used commercially 
avaliable factor concentrates and US blood donors7 and  pa- 
tients.','" 
T 
MATERIALS AND METHODS 
Serum samples were separated on  the day of collection and stored 
at -70°C. Virus RNA was extracted from stored serum samples 
by incubation with proteinase Wsodium dodecyl sulfate (SDS) as 
described previously.* HCV  RNA  was reverse transcribed and ampli- 
fied  by polymerase chain reaction (PCR) using nested primers match- 
ing conserved regions in the 5' noncoding region (NCR)." Product 
DNAs were cleaved with restriction enzymes HaeIIYRsa I and Mva 
VHinf16 and  the resultant (restriction fragment length polymorphism 
[REP])  patterns used to identify the different major genotypes of 
HCV. Subsequent digestion of product DNAs with restriction en- 
zymes BstUI and ScrFI allowed the identification of HCV subtypes 
la and lb  (BstUI) and 2a, 2b, 3a and 3b ( S C ~ F ' I ) . ~  Restriction frag- 
Thailand) but in each, the HCV genotype distributions in 
hemophiliacs and blood donors were similar. In addition, 
HCV  genotypes in rscipients of commercially  manufactured 
concentrates were similiar to those found in  the US general 
population. These findings provide no evidence that HCV 
genotypes  differ  significantly from each other in replication 
rate,  transmissibility, or infectivity. 
0 7 9 9 6  by  The  American  Society of Hematology. 
ments were separated by agarose gel electrophoresis using 4% Meta- 
phor agarose (FMC Bioproducts, Rockland, ME).7,8 Direct nucleo- 
tide sequencing of  PCR products was performed as described 
previously." 
RESULTS 
HCV RNA from serum samples of 372 hemophiliacs from 
six different countries was amplified in the 5' NCR by re- 
verse transcriptase-PCR (RT-PCR). Virus genotype was de- 
duced by cleavage of product RNAs cleaved with restriction 
The HCV genotype distributions in cohorts that had been 
multiply transfused only  with factor concentrates or cryopre- 
cipitates manufactured locally were markedly different be- 
tween countries. In Hungary all except one patient were 
infected with HCV genotype Ib (95%) (Fig lA), whereas 
in Scottish hemophiliacs types l a  (44%) and  3a (31%) were 
the most prevalent with fewer examples of types 1 b ( 1  1 %), 
2a (l%), 2b (5%), and 5 (1%) (Fig IB). In the cohort of 
hemophiliacs from Johannesburg, South Africa, genotypes 
1 through 5 were present, but genotype 5 (36%) was most 
frequent (Fig 1C). Hemophiliacs from Thailand were princi- 
pally infected with type 3 (57%), although a significant pro- 
portion ( 1  5%) were infected with a series of novel genotypes 
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similar to those described in Vietnam," Indonesia," and 
ThaiIand.l4." These novel genotypes (with type 6) form a 
particular heterogeneous genotype distributed widely 
throughout Southeast AsiaIs and in this study, have been 
classified together and labeled 6* (Fig 1D). 
Comparisons of these distributions were made with those 
of the corresponding blood donor populations7 (Fig 1 A-D). 
For each country the observed HCV genotype frequencies in 
the hemophiliac cohorts closely mirrored the distinct patterns 
found in the corresponding blood donors. For example, the 
new HCV variants found in Thai hemophiliacs (described 
above as 6*) accounted for 15% of the infections in hemo- 
philiacs and 16% in Thai blood donors. Similarly, 95% of 
the hemophiliacs in the Hungarian cohort were infected with 
genotype lb as were 85% of the Hungarian blood donors 
surveyed. The predominant genotype in South African blood 
donors, equally common in black  and white racial g r o ~ p s , ~  
was found to be type 5 (SS%),  and again this distribution was 
reflected in the corresponding hemophiliac cohort (36%). 
In contrast, six cohorts of hemophiliacs, from the United 
Kingdom (Sheffield," Nottingham, Edinburgh), Germany, 
South Africa, and Hungary, which had received commercial 
factor concentrate (largely manufactured from US plasma), 
were most frequently infected with types la or Ib (3676, 
27%). Genotype frequencies were similar in each country 
(data not shown) and resembled those found in US volunteer 
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Fig 1. HCV genotype distri- 
bution in hemophiliacs (M) and 
blood donors7 ( 8 )  from Hungary 
(A), Scotland (B), South Africa 
(C), and Thailand (D). All hemo- 
philiacs were treated with factor 
concentrates prepared from lo- 
cal blood donors. Vertical axes 
show numbers of patients. 
blood donors7 and US patients with chronic HCV infec- 
tion".'" (Fig 2). 
Infection with  more  than one genotype, as determined by 
RFLP analysis, was infrequently detected in both hemophili- 
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Fig 2. HCV genotype distribution in hemophiliacs treated with 
commercial factor concentrates ( W ,  chronically infected US nonhe- 
mophiliac patient^^,'^ (9). and volunteer US blood donors7 (01. Verti- 
cal  axes show numbers of patients. 
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acs who received local (1 %) and commercial concentrates 
(3%). However, this method will only detect the predominant 
variant and others genotypes may be present at low frequen- 
cies. 
DISCUSSION 
The absence of blood donor screening for HCV  and use 
of nonvirally inactivated pooled clotting factor concentrates 
has exposed hemophiliacs to multiple episodes of  HCV in- 
fection for a period of at least 10  year^."^ Despite the oppor- 
tunity for more pathogenic variants of HCV to establish 
infection in hemophiliacs, we have found no evidence for 
over or underrepresentation of HCV genotypes in these pa- 
tients compared with those to which they were exposed. 
The availability of data from several countries with different 
genotype distributions in the general population' allowed 
comparisons of the relative pathogenicities of several geno- 
types to be compared (eg, types l a  and 3a in Scotland, types 
1 and 5 in South Africa, and types 3a, 1, and 6* in Thailand). 
Population differences in susceptibility to infection with 
different genotypes (such as variation in the frequency of 
different HLA alleles) could be ruled out as an explanation 
for the genotype differences observed because the genotype 
distribution in the hemophiliacs treated with commercial fac- 
tor concentrates differed markedly from those found in the 
local blood donors. Indeed, for commercial factor users in 
each country (Germany, Hungary, South Africa, and United 
Kingdom) the same distribution of genotypes was observed 
as that of the US population (the main source of such blood 
products). Overall the similarity between hemophiliacs and 
blood donor genotypes strongly suggests that there are no 
significant differences between genotypes in replication rate, 
transmissibility, or susceptibility to immune clearance. 
An alternative explanation for the similarity in genotype 
distribution between hemophiliacs and blood donors is  that 
hemophiliacs became infected with the first genotype that 
they were exposed to and that this induced a protective im- 
mune response that prevented reinfection with other geno- 
types. However, there is no evidence for protective immunity 
in experimental animals reexposed to HCV,'7,'8 and repeated 
transfusion of HCV contaminated blood in thalassemic chil- 
dren led to symptomatic reinfe~tion.'~ Furthermore, direct 
evidence against protective immunity in the study group 
includes the detection of mixed infections in some hemophil- 
type with  time.' Indeed, in a longitudinal study of hemophili- 
acs in the Edinburgh cohort, we found genotype changes 
from type 1 ( la  or lb) to other genotypes as frequently as 
changes from other genotypes to type 1, providing further 
evidence for a lack of difference in pathogenicity between 
HCV variants.8 
This study provides no evidence to support previous 
suggestions of a greater replicative capacity of HCV type 
because if this were the case, type 1 should be more 
frequently detected in multiply exposed individuals. Instead, 
this study is consistent with recent studies reporting similar 
virus loads for all genotypes, once the difference in sensitiv- 
ity of assays such as branched DNA for different genotypes, 
iaCs,16,20-22 and changes in the predominant circulating geno- 
19.10.23.26 
is con~idered .~~.~"  Similarly, measurement of virus load by 
PCR-based methods usually find no differences in virus lev- 
els between genotypes.29s30 
The proposed greater pathogenicity of type lb3L.32 would 
be expected to lead to the replacement of other genotypes 
from hemophiliacs with  time,  if  it were associated with the 
development of more rapidly progressive liver disease. The 
failure of any one genotype to replace others in this study 
is inconsistent with such differences. It may be possible to 
argue that at least some of the previous studies showing a 
greater propensity for type l b  to cause more severe liver 
d i ~ e a s e ~ , ~ ' . ~ ~  did not adequately control for compounding 
variables such as age, duration, and route of infection that 
may also show association with genotype and progression. 
In a large multivariate analysis of the development of cirrho- 
sis in HCV-infected individuals, age was the only factor 
that was significant. Allowing for age, genotype showed no 
influence on the likelihood of development of cirrh~sis.'~ 
Greater response rates to interferon (IFN) have been con- 
sistently found among individuals infected with  HCV  geno- 
types 2 and 3 compared to type lb  (or type 1) in Japan, 
Europe, and the United  state^.^^.^^ This difference remains 
even when other compounding factors such as patient age 
and pretreatment severity of disease have been accounted 
for.38 In the Edinburgh hemophilia cohort, only hemophiliacs 
infected with genotype 3a showed any response to conven- 
tional 3 MU a-IFN three times per week, where six of seven 
normalized alanine transaminase levels and cleared viremia 
during treatment (compared with none of 18 type 1 infected 
 individual^).'^ In  view of the findings presented in this study, 
it appears unlikely that such genotype-specific differences 
in response can be attributed directly to pretreatment disease 
severity, variation in the propensity of certain variants to 
persist through a greater replication rate, or a decrease in 
the effectiveness of cytotoxic T cells to clear infection of 
the liver, although each of these may play an independent 
role in determining response. Instead it implies that there 
exist intrinsic differences between genotypes in their suscep- 
tibility to the antiviral action of IFN. The elucidation of 
the mechanism of resistance may provide an important step 
toward the development of more effective treatment for HCV 
infection in the future. 
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